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Abstract The post-thrombotic syndrome (PTS) is a fre-
quent, potentially disabling complication of deep vein
thrombosis (DVT) that reduces quality of life and is costly.
Clinical manifestations include symptoms and signs such
as leg pain and heaviness, edema, redness, telangiectasia,
new varicose veins, hyperpigmentation, skin thickening
and in severe cases, leg ulcers. The best way to prevent
PTS is to prevent DVT with pharmacologic or mechanical
thromboprophylaxis used in high risk patients and settings.
In patients whose DVT is treated with a vitamin K antag-
onist, subtherapeutic INRs should be avoided. We do not
suggest routine use of elastic compression stockings (ECS)
after DVT to prevent PTS, but in patients with acute DVT-
related leg swelling that is bothersome, a trial of ECS is
reasonable. We suggest that selecting patients for catheter-
directed thrombolytic techniques be done on a case-by-case
basis, with a focus on patients with extensive thrombosis,
recent symptoms onset, and low bleeding risk, who are
seen at experienced hospital centers. For patients with
established PTS, we suggest prescribing 20–30 mm Hg
knee-length ECS to be worn daily. If ineffective, a stronger
pressure stocking can be tried. We suggest that intermittent
compression devices or pneumatic compression sleeve
units be tried in patients with moderate-to-severe PTS
whose symptoms are inadequately controlled with ECS
alone. We suggest that a supervised exercise training pro-
gram for 6 months or more is reasonable for PTS patients
who can tolerate it. We suggest that management of post-
thrombotic ulcers should involve a multidisciplinary
approach. We briefly discuss upper extremity PTS and PTS
in children.
Keywords Post-thrombotic syndrome  Venous
thromboembolism  Deep venous thrombosis  Direct oral
anticoagulants (DOAC)  New oral anticoagulants (NOAC)
Introduction
The post-thrombotic syndrome (PTS) is a chronic condition
that develops in *20–50 % of patients after deep venous
thrombosis (DVT) [1]. It adversely affects health and
quality of life, and is costly as measured by health care
costs, out of pocket expenditures, and lost productivity.
The objective of this chapter is to provide guidance for
the general practitioner, internist, nurse practitioner, phar-
macist, and other healthcare professionals on best current
practices for the prevention and treatment of PTS.
Background
Traditionally, clinical trials investigating new therapies or
management approaches to treat DVT have focused on
their effectiveness to prevent recurrent venous throm-
boembolism (VTE) in the short (3 months) to medium term
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(12 months) after DVT, while their effectiveness to prevent
PTS has been ignored. Over the last 10–15 years, however,
PTS has been increasingly recognized as a frequent and
important outcome of DVT. Recent studies have improved
understanding of the epidemiology, risk factors, and health
and economic impact of PTS. Recommendations for stan-
dardization of the definition of PTS for clinical studies
have been published [2], and rigorous clinical trials are
underway to evaluate new approaches to preventing and
treating PTS. Recently, the first evidence-based guidelines
focused solely on PTS were published by the American
Heart Association [3].
Methods
To provide guidance on the management of the post-
thrombotic syndrome, we first developed a number of
pivotal practical questions pertaining to the PTS (Table 1).
Questions were developed by consensus from the authors.
The literature addressing the questions below was reviewed
by searching electronic databases (PubMed, Medline) and
the authors’ personal libraries, with a focus on high quality
cohort studies and randomized controlled trials published
in the last 10 years, where available. For each question, a
brief summary and interpretation of pertinent literature and
existing guidelines, where available, are provided, fol-
lowed by guidance for the reader.
Guidance
(1) What is PTS and why is it important (i.e. epidemi-
ology, impact on quality of life, cost)?
PTS is a clinical disorder of pain and disability resulting
from chronic venous insufficiency following DVT. PTS is
the most frequent complication of DVT. It develops in
*20–50 % of patients within 2 years of DVT diagnosis [4,
5], even when patients are adequately treated with antico-
agulants, and is severe in 5–10 % of cases. Hence on
average, about 6 of 10 DVT patients recover without any
residual symptoms, 3 of 10 have some degree of PTS, and
*1 of 10 to 1 of 20 develop severe PTS that can include
pain leg ulcers. The overall estimated incidence of VTE is
0.7–2 per 1000 person-years and increases with age [6, 7]
so that more than one-third of cases occur in persons older
than 60 years of age [8]. VTE is a growing public health
problem due to increased life expectancy, an increasing
proportion of elderly individuals and an expected increase
in the prevalence of PTS.
Due to its high prevalence and chronicity, PTS is a
costly condition. A Canadian study estimated that the total
per-patient cost of PTS over a two-year period was almost
50 % higher than for DVT patients without PTS [9]. Costs
were largely attributable to frequent healthcare visits and
prescription medications. In the United States, annualized
median total costs for DVT patients who developed PTS
was $20,569 compared with $15,843 in matched controls
with DVT and no PTS [10]. Costs are highest in those with
PTS who develop venous ulcers, due to surgery, lost
workdays and loss of employment [11]. It is estimated that
2 million workdays are lost annually in the United States
due to leg ulcers [12].
Studies have shown that compared to DVT patients
without PTS, patients with PTS have poorer quality of life
[13–16] and scores worsen as severity of PTS increases
[17]. Notably, PTS patients report worse quality of life
scores than average scores for patients with osteoarthritis,
diabetes and chronic lung disease [16].
Guidance Statement Not applicable.
(2) What are the clinical manifestations of PTS and what
is its underlying pathophysiology?
The clinical manifestations of PTS are similar to those
of primary venous insufficiency and include a constellation
of symptoms and signs which vary from patient to patient
[18] (Table 2). Typical symptoms include leg pain, a sen-
sation of leg heaviness, pulling or fatigue, and leg swelling.
Typical signs may include leg edema, redness, dusky
cyanosis when the leg is in a dependent position, telang-
iectasia, new varicose veins, stasis hyperpigmentation, skin
thickening and in severe cases, leg ulcers. The severity of
symptoms and signs ranges from minimal discomfort and
cosmetic concerns to severe clinical manifestations such as
chronic pain, intractable edema, and leg ulceration [1, 19].
The intensity of symptoms and signs increases over the
course of the day.
Table 1 Guidance questions to be considered
(1) What is PTS and why is it important (i.e. epidemiology, impact
on quality of life, cost)?
(2) What are the clinical manifestations of PTS and what is its
underlying pathophysiology?
(3) How is PTS diagnosed?
(4) What are known risk factors for PTS?
(5) Is there a best anticoagulant to treat DVT that influences the
occurrence of PTS?
(6) What are current best approaches to preventing PTS after
DVT?
(7) What are current best approaches to treating PTS?
(8) Does PTS occur after upper extremity DVT?
(9) Does PTS occur after DVT in children?
(10) What are the most pressing research needs in the field?
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PTS is thought to develop after DVT due to venous
hypertension (i.e. increased venous pressures) [20]. Venous
hypertension leads to reduced calf muscle perfusion,
increased tissue permeability and the associated clinical
manifestations of PTS. Two pathological mechanisms
contribute to venous hypertension: persistent (acute, then
residual) venous obstruction (RVO) and valvular reflux
caused by vein valve damage [21]. Inflammation may play
a role in promoting the development of PTS by delaying
thrombus resolution and by inducing vein wall fibrosis,
which promotes valvular reflux [22, 23]. There may also be
a genetic predisposition to PTS from gene polymorphisms
associated mainly with vein wall remodelling [24].
Guidance Statement Not applicable.
(3) How is PTS diagnosed?
There is no gold standard laboratory, imaging, or func-
tional test that establishes the diagnosis of PTS. PTS is
primarily diagnosed on clinical grounds, based on the
presence of typical symptoms and signs in a patient with
previous DVT. Symptoms of PTS can be present in various
combinations and may be persistent or intermittent.
Symptoms tend to be aggravated by standing or walking
and tend to improve with rest and leg elevation. In some
patients, it can take a few months for the initial pain and
swelling associated with acute DVT to resolve, thus a
diagnosis of PTS should be deferred until after the acute
phase (i.e. 3–6 months) has passed. Symptoms of PTS
usually occur within 3–6 months after DVT, but can occur
up to 2 years after DVT [25].
The Villalta PTS scale (sometimes called the Villalta-
Prandoni scale) [26] has been adopted by the International
Society on Thrombosis and Haemostasis (ISTH) as a
standard to diagnose and grade the severity of PTS in
clinical studies [2]. The scale’s components (5 symptoms
and 6 signs) are each rated on a 4-point severity scale, and
the points are summed to produce a total score; a score[4
denotes PTS (Table 3). The Villalta PTS scale has been
shown to be valid, reproducible, and responsive to clinical
change, and is easy to administer [27]. The Villalta PTS
scale has been used to diagnose PTS in a number of recent
randomized trials of interventions to prevent and treat PTS
[28–32]. Additional diagnostic scales have been used to
assess PTS, including the CAEP classification and Gins-
berg measure; these are discussed in reference 2.
Guidance Statement We suggest that in patients with a
history of VTE, the Villalta PTS scale be used to assess the
presence and severity of the PTS.
(4) What are known risk factors for PTS?
While it is not yet possible to precisely predict the
absolute risk of PTS in an individual patient with DVT,
research done over the last 10 years has provided new
information on various risk factors for PTS [1, 33]. This
information is summarized below; the strongest risk factors
are indicated with*:
Risk factors apparent at time of DVT diagnosis
• Age: Older age increases the risk of PTS.
• Elevated body mass index (BMI): Increased risk of
PTS.
• Pre-existing primary venous insufficiency: Increased
risk of PTS [34, 35].
• Characteristics of initial DVT: Risk of PTS is higher
(2–3-fold) after proximal (especially with involvement
of the iliac or common femoral vein) than distal (calf)
DVT. Whether DVT was unprovoked vs. secondary
(e.g. due to recent surgery, trauma, immobilization or
active cancer) does not appear to influence the risk of
developing PTS [5, 29].
Table 2 Typical clinical features of the PTS
Leg symptoms Signs









Symptom pattern: worse with activity,
standing, walking, better with rest, lying
down, maximum at end of day
Healed ulcer(s) or
open ulcer(s)
Table 3 Villalta PTS scale [2, 26]
Criteria used to diagnose PTS
Assessment of
5 symptoms (pain, cramps, heaviness, pruritus, paresthesia) by
patient self-report
6 signs (edema, skin induration, hyperpigmentation, venous ectasia,
redness, pain during calf compression) by clinician assessment
Severity of each symptom and sign is rated as 0 (absent), 1 (mild), 2
(moderate) or 3 (severe)




15 or more, or presence of ulcer: severe PTS
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• Gender, Inherited thrombophilia: No consistent rela-
tionship with PTS [33, 36].
Risk factors related to treatment of acute DVT
• Quality of oral anticoagulation: PTS risk increases
(twofold) if level of anticoagulation is inadequate (e.g.
subtherapeutic INR[ 50 % time) during the first
3 months of treatment with vitamin K antagonists
[37, 38].
Risk factors apparent during follow-up after DVT
• *Recurrent ipsilateral DVT: Increases risk of PTS by
4–6-fold, presumably by damaging compromised
venous valves or aggravating venous outflow obstruc-
tion [4, 5].
• Persistent venous symptoms/signs 1 month after acute
DVT: Increased risk of subsequent PTS [5, 39].
• Residual thrombosis on ultrasound (e.g. 3–6 months
after acute DVT): Modest (1.5–2-fold) increased risk of
PTS [40].
• Persistent elevation of D-dimer: Elevated levels of
D-dimer in the weeks to months after DVT may be a
modest risk factor for PTS [41].
Guidance Statement Not applicable.
(5) Is there a best anticoagulant to treat DVT that
influences the occurrence of PTS?
It is not known whether use of the new direct, target-
specific oral anticoagulants to treat DVT influences the risk
of PTS, compared to treatment with low molecular weight
heparin (LMWH) and vitamin K antagonists [42]. Inter-
estingly, some data suggest that use of LMWH
monotherapy to treat DVT may lead to lower rates of PTS
than standard treatment with LMWH followed by vitamin
K antagonists [43]. These data require confirmation in
large, well-designed RCTs.
Guidance Statement Data are insufficient to make any
recommendations regarding choice of anticoagulant,
specifically a vitamin K antagonist vs. a target-specific oral
anticoagulant, on the outcome of developing PTS.
(6) What are current best approaches to preventing PTS
after DVT?
Primary prevention of DVT
Guidance Statement The best way to prevent PTS is to
prevent the occurrence of DVT. We therefore suggest the
use of pharmacologic or mechanical thromboprophylaxis
to prevent VTE in high risk patients and settings, as
recommended in evidence-based consensus guidelines
[44–46].
Prevention of DVT recurrence
As ipsilateral DVT recurrence is an important risk factor
for PTS, preventing recurrent DVT by providing optimal
anticoagulation of appropriate intensity and duration for
the initial DVT is a key goal [47]. For specific suggestions
on optimal anticoagulation to treat DVT, the reader is
referred to the chapter in this volume titled ‘Guidance for
the treatment of DVT and PE.
Guidance Statement In patients whose DVT is treated
with a vitamin K antagonist, frequent, regular INR moni-
toring should be performed to avoid subtherapeutic INRs,
especially in the first 3 months of treatment.
Elastic compression stockings
Elastic compression stockings (ECS), by reducing edema
and venous hypertension, could plausibly play a role in
preventing PTS. However, there are conflicting data on the
long term effectiveness of ECS to prevent PTS. Two pre-
vious small, randomized, open label trials reported that
wearing 30–40 mm Hg knee-high ECS for at least 2 years
after proximal DVT was effective in preventing PTS [29,
48]. Based on these data, evidence-based consensus
guidelines have recommended the use of ECS for at least
2 years after DVT to prevent PTS [47, 49]. However, a
recent large (n = 803), multicenter, randomized, placebo-
controlled trial showed no evidence of benefit of active
compression stockings, worn for 2 years after proximal
DVT, to prevent PTS: rates of PTS, recurrent VTE and
QOL scores were similar in the active and placebo stock-
ings groups [31]. Further, a secondary analysis of that trial
showed no difference in pain scores during the first 60 days
after DVT in the active and placebo stockings groups. The
placebo-controlled blinded design of this trial is an
important methodological strength, owing to the subjective
nature of PTS assessment [50].
Guidance Statement Based on these data, we do not
suggest the routine use of ECS to prevent PTS in DVT
patients, or to relieve acute DVT-related pain. However,
because the trials cannot rule out a benefit of ECS in small
sub-groups of patients or even to exploit a placebo benefit
of ECS in patients with acute DVT-related leg swelling that
is bothersome or uncomfortable, a trial of 20–30 mm Hg or
30–40 mm Hg ECS is not unreasonable.
Thrombolysis
Upfront thrombolytic therapy in conjunction with heparin
to treat acute DVT leads to higher rates of vein patency and
better preservation of valve function than the use of heparin
Guidance for the prevention and treatment of the post-thrombotic syndrome 147
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alone [21, 51]. Catheter-directed thrombolysis (CDT) or
pharmacomechanical CDT (catheter-directed thromboly-
sis ? mechanical disruption of thrombus) are likely to be
safer and more effective than systemic thrombolytic ther-
apy and could hold promise as a means of preventing PTS,
primarily after proximal DVT [52]. In one multicenter
randomized controlled trial of modest (n = 189) size, the
use of additional CDT in anticoagulated patients with acute
DVT involving the iliac and/or upper femoral vein was
associated with a 26 % reduction in the risk of developing
PTS over 2 years follow-up, with an additional 3 % rate of
major bleeding [30]. Larger multicenter trials of PCDT?
standard anticoagulation vs. standard anticoagulation alone
to prevent PTS are ongoing [53, 54] and results are
expected within 1–2 years. The role of thrombolysis and
other endovascular approaches in the management of DVT
is discussed in greater depth in the Guidance for the use of
Thrombolytic Therapy for DVT and PE chapter in this
volume.
Guidance Statement We suggest that selection of
patients for catheter-directed thrombolytic techniques
should be done on a case-by-case basis, with a predomi-
nant focus on patients with extensive (e.g. iliofemoral)
thrombosis, recent onset of symptoms, low risk of bleeding
and long life expectancy, [47] who are seen at hospital
centers experienced in performing these techniques.
(7) What are current best approaches to treating estab-
lished PTS?
Compression-based therapies
A number of compression-based therapies have been used
with the goals of reducing PTS symptoms (especially leg
swelling and discomfort) and improving daily functioning.
However, few controlled studies of their effectiveness have
been performed, and available controlled studies are small,
with limited follow-up time. Therefore, the suggestions
below are based primarily on the low risk of harm and the
possibility of benefit to at least some patients.
Guidance Statement We suggest the following man-
agement approach for compression-based therapies: Pre-
scribe 20–30 mm Hg ECS to patients with PTS-related leg
heaviness or swelling. We suggest knee-length ECS, which
have similar physiologic effects to thigh-length ECS and
are easier to apply, more comfortable and less costly.
Explain to the patient that these are to be worn daily, from
waking to retiring. If 20–30 mm Hg ECS do not adequately
control PTS symptoms, a stronger pressure stocking
(30–40 mm Hg; or 40–50 mm Hg) can be tried [32]. We
suggest that the portable, battery-powered Venowave
intermittent compression device be tried in patients with
moderate to severe PTS whose symptoms are not ade-
quately controlled with ECS alone [28, 47]. We suggest
that intermittent pneumatic compression sleeve units (e.g.
used for 20–30 min sessions, 2–3 times per day) can be
used to help severe, intractable PTS symptoms or severe
edema [55], however patients may find these to be cum-
bersome and the units are expensive.
Pharmacotherapy
Four randomized trials have been performed to evaluate the
effectiveness of ‘‘venoactive’’ drugs for PTS: three parallel
trials [56–58] and one crossover study [59]. The drugs
evaluated were rutosides (thought to reduce capillary fil-
tration and microvascular permeability), defibrotide (down-
regulates plasminogen activator inhibitor-1 release and up-
regulates prostacyclin, prostaglandin E2, and thrombo-
modulin), and hidrosmin (mechanism of action unknown)
[60]. Overall, there is low-quality evidence to support the
use of venoactive drugs to treat PTS as studies were limited
by a high degree of inconsistency and imprecision [60].
Also, as drug treatment was usually of short duration (e.g.
8 weeks to a few months), potential long-term side effects
are unknown.
Guidance Statement We do not suggest the use of
venoactive drugs to treat PTS. Also, due to an absence of
evidence and potential for harm, we do not suggest the use
of diuretics to treat PTS-related edema.
Exercise and lifestyle
Two small trials have assessed the effectiveness of exercise
to treat PTS. In a study of 30 patients with chronic venous
insufficiency (half had prior DVT), a six month leg muscle
strengthening exercise program led to improved calf mus-
cle function and calf muscle strength [61]. In a two-center
Canadian pilot study, a 6 month program of exercise
training that consisted of exercises to increase leg strength,
leg flexibility and overall cardiovascular fitness improved
PTS severity, quality of life, leg strength and leg flexibility,
and there were no adverse events [62]. While not definitive,
the available data suggest that exercise may benefit patients
with PTS.
Common sense advice that is relevant to all patients
with chronic venous insufficiency includes: promote
venous return by avoiding a sedentary lifestyle, raising the
legs on a stool when seated or elevating the legs in bed
when lying down; avoid prolonged exposure to heat;
maintain a healthy, non-obese body weight; and use a
moisturizing cream to avoid skin dryness.
Guidance Statement We suggest that a supervised
exercise training program consisting of leg strengthening
148 S. R. Kahn et al.
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Table 4 Summary of guidance statements
Question Guidance statement
(1) What is PTS and why is it important? Not applicable; see text
(2) What are the clinical manifestations of PTS and
what is its underlying pathophysiology?
Not applicable; see text
(3) How is PTS diagnosed? We recommend that in patients with a history of VTE, the Villalta PTS scale be used
to assess the presence and severity of the PTS
(4) What are known risk factors for PTS? Not applicable; see text
(5) Is there a best anticoagulant to treat DVT that
influences the occurrence of PTS?
Data are insufficient to make any recommendations regarding choice of anticoagulant,
specifically, a vitamin K antagonist vs a target-specific oral anticoagulant, on the
outcome of developing PTS
(6) What are current best approaches to preventing PTS
after DVT?
For primary prevention
Prevent the index DVT with use of thromboprophylaxis in high-risk patients and
settings as recommended in evidence-based consensus guidelines
For prevention of recurrent DVT
In patients whose DVT is treated with a vitamin K antagonist, frequent, regular INR
monitoring should be performed to avoid subtherapeutic INRs, especially in the first
3 months of treatment
Value of elastic compression stockings
We do not suggest the routine use of ECS to prevent PTS in DVT patients, or to
relieve acute DVT-related pain. However, in patients with acute DVT-related leg
swelling that is bothersome or uncomfortable, we suggest a trial of 20–30 mm Hg or
30–40 mm Hg ECS to relieve edema
Value of thrombolysis
The role of thrombolysis for the prevention of PTS is not yet established. In
particular, pharmacomechanical catheter-directed thrombolysis requires further
evaluation in properly designed trials. For now, we suggest that selection of patients
for these techniques should be done on a case-by-case basis, and mainly considered
for select patients with extensive thrombosis, recent onset symptoms, low bleeding
risk and long life expectancy
(7) What are current best approaches to treating PTS? Elastic compression stockings
We suggest the use of 20–30 mm Hg (or stronger, if ineffective) ECS to reduce
edema and improve PTS symptoms
We suggest a trial of intermittent pneumatic compression devices in patients with
moderate to severe symptomatic PTS
Pharmacotherapy
We do not suggest the use of venoactive drugs to treat PTS. Also, due an absence of
evidence and potential for harm we do not suggest the use of diuretics to treat PTS-
related edema.
Exercise and lifestyle
We suggest that a supervised exercise training program with leg strengthening and
aerobic components for 6 or more months be tried in PTS patients who can tolerate
it
Management of venous ulcers
We suggest a multidisciplinary approach to venous ulcer management, which usually
consists of compression therapy, skin care and topical dressings
In patients with symptoms of upper extremity PTS, we suggest a trial of a 20–30 mm
Hg or 30–40 mm Hg compression sleeve
(8) Does PTS occur after upper extremity DVT? Due to potential for benefit and low potential for harm, we suggest a trial of a
20–30 mm Hg or 30–40 mm Hg compression sleeve in patients with symptoms of
upper extremity PTS
(9) Does PTS occur after DVT in children? At present, we suggest that symptomatic management of PTS in children should
generally follow adult guidelines, and that where possible, pediatricians with
expertise in thromboembolism should manage pediatric patients with DVT
Guidance for the prevention and treatment of the post-thrombotic syndrome 149
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and aerobic activity for 6 months or more is reasonable for
PTS patients who can tolerate it.
Venous ulcer management
Five to 10 % of DVT patients develop severe PTS, which
can include leg ulcers. Post-thrombotic venous ulcers are
treated with compression therapy, leg elevation, topical
dressings and sometimes hemorheological agents like
pentoxifylline but can be refractory to therapy and tend to
recur.
Guidance Statement We suggest that ideally, manage-
ment of patients with post-thrombotic ulcers involves a
multidisciplinary approach that includes an internist, der-
matologist, vascular surgeon and wound care nurse. For
more detailed discussion of venous ulcer management,
please refer to recent published reviews [63, 64] and
consensus guidelines [3].
Surgical or endovascular treatments for PTS
Surgical or endovascular procedures such as venous valve
repair, venous bypass and venous stents to treat appropri-
ately selected PTS patients have potential to decrease post-
thrombotic manifestations that are attributable to deep vein
obstruction or VR [65, 66]. However, because well-de-
signed studies have not been performed to date, experience
with these procedures varies substantially among provi-
ders, and rates of complications and failure are uncertain,
these interventions should not be routinely utilized in
unselected PTS populations. Rather, the opportunity to
consult with an endovascular subspecialist who is experi-
enced with the assessment and management of complex
venous disease may be appropriate to discuss with selected
patients with moderate-to-severe PTS who have substantial
disability and life limitations. For more detailed discussion
of surgical and endovascular treatments for PTS, please
refer to a recently published AHA consensus guideline [3].
(8) Does PTS occur after upper extremity DVT?
After upper extremity DVT, 15–25 % of patients will
develop PTS [67, 68]. As with lower limb PTS, upper
extremity PTS can reduce quality of life and limb function
[69, 70]. Not surprisingly, dominant arm PTS is associated
with worse quality of life and disability than non-dominant
arm PTS [69]. Data to guide the management of upper
extremity PTS are lacking. There have been no trials of
compression sleeves or bandages to prevent or treat upper
extremity PTS, and it is not known whether thrombolysis,
endovascular or surgical treatment of UEDVT results in
lower rates of PTS than standard anticoagulation alone.
Guidance Statement Due to potential for benefit and
low potential for harm, we suggest a trial of a 20–30 mm
Hg or 30–40 mm Hg compression sleeve in patients with
symptoms of upper extremity PTS.
(9) Does PTS occur after DVT in children?
The incidence of PTS is reported to be as high as 15–25 %
in children with DVT [71, 72]. There are no pediatric
studies that have evaluated the safety and effectiveness of
therapies to prevent or treat PTS.
Guidance Statement At present, we suggest that
symptomatic management of PTS in children should gen-
erally follow adult guidelines, and that where possible,
pediatricians with expertise in thromboembolism should
manage pediatric patients with DVT.
(10) What are the most pressing research needs in the
field?
• Mechanistic studies to improve our understanding of
the pathophysiology of PTS and to suggest future
therapeutic targets
• Development of risk prediction indices to predict risk
of PTS at the time of DVT diagnosis, in order to help
guide the longitudinal management of patients with
DVT
• Study of the role of risk factor modification (e.g. weight
reduction, exercise) to prevent or treat PTS
• Assessment of the impact and cost-effectiveness of
direct, target specific oral anticoagulants on the risk of
PTS
• Assessment of the effectiveness, tolerability and cost-
effectiveness of extended LMWH therapy to prevent
PTS
• Studies of the effectiveness, safety and cost-effective-
ness of PCDT to treat DVT as a means to prevent PTS
• Studies of the effectiveness of ECS and other com-
pression modalities to treat lower extremity PTS, upper
extremity PTS and pediatric PTS
• Assessment of the role of CDT/PCDT for prevention of
upper extremity PTS and pediatric PTS
• Rigorous evaluation of the safety and long-term
effectiveness of endovascular and surgical procedures
to treat severe PTS
Conclusion
PTS is a frequent complication of DVT that has the
potential to reduce quality of life and lead to chronic
functional disability. In this chapter, we have tried to
provide guidance on key aspects relating to the diagnosis,
risk factors, prevention and treatment of PTS (Table 4).
Based on the numerous gaps in knowledge of PTS, we have
also identified important areas for further research.
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